C4 Therapeutics Q2 Net Loss $23.6M, EPS $0.18; Cemsidomide Trials On Track
C4 Therapeutics reported a net loss of $23.6 million, or $0.18 per share, for Q2 2026, an improvement from a net loss of $26.0 million, or $0.37 per share, in Q2 2025. Revenue for the quarter was $6.6 million, slightly up from $6.5 million year-over-year. The company's cash, cash equivalents, and marketable securities stood at $300.4 million as of June 30, 2026, providing a cash runway until the end of 2028. Key clinical programs for cemsidomide, including the Phase 2 MOMENTUM trial and Phase 1b combination trials, remain on track for data readouts in 2027, alongside a new collaboration with Roche and $33.5 million raised through its ATM program.
Key Highlights
- Net loss for Q2 2026 was $23.6 million, down from $26.0 million in Q2 2025.
- Net loss per share for Q2 2026 was $0.18, compared to $0.37 in Q2 2025.
- Total revenue for Q2 2026 was $6.6 million, up from $6.5 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $300.4 million as of June 30, 2026.
- Company expects current cash to fund operations until the end of 2028.
- Received a $20 million upfront payment from the new Roche DAC collaboration in May 2026.
- Raised approximately $33.5 million in net proceeds through its ATM program in Q2 2026.
- Cemsidomide Phase 2 MOMENTUM trial is on track for initial ORR data in 2H 2027.
Price Impact
More from CCCC
C4 Therapeutics Presents Positive Biomarker Data for Cemsidomide in Multiple Myeloma Trials
C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
C4 Therapeutics Stockholders Elect Directors, Approve Plan Amendment